Becton, Dickinson and Company

Equities

BDX

US0758871091

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:02 2024-04-25 pm EDT			5-day change	1st Jan Change
230.5 ^USD	-1.43%		-1.15%	-5.48%

Apr. 05	Becton Dickinson Releases New Image-Enabled Cell Sorters	MT
Apr. 05	Becton, Dickinson and Company Increases Access to Cutting-Edge Image-Enabled, Spectral Cell Sorters	CI

Becton Dickinson and : Q3 2020 Earnings Presentation

August 06, 2020 at 06:09 am EDT

Third Quarter Results Fiscal Year 2020

August 6, 2020

Forward-Looking Statements

These materials include forward-looking statements and it's possible that actual results could differ from our expectations. Factors that could cause such differences appear in our earnings release furnished as an exhibit to the Form 8-k that BD filed today with the SEC, and in our recent SEC filings.

Non-GAAP Financial Measures

These materials also include Non-GAAP financial measures. A reconciliation to the most directly comparable GAAP measures can be found herein, or in our earnings release and the financial schedules attached thereto.
Certain financial information excludes the impact of foreign currency translation
Basis of Presentation for Revenue Growth Metrics: All revenue amounts are presented on a GAAP basis. FXN revenue growth reflects growth on a currency neutral basis.
A copy of our earnings release, including the financial schedules, is posted on the "Investors" section of the BD.com website.

Footnotes

1.Figures other than Revenue and Preferred Dividend are "as adjusted" which exclude, among other things, the impact of purchase accounting adjustments (including the non-cash amortization of acquisition-related intangible assets); integration, restructuring and transaction costs.

Note: COVID impact represents BD's estimate of the net financial impact of the global COVID-19 pandemic on the Company's results. Revenue growth rates are not adjusted to reflect the impact of COVID-19.

Q3 Overview

Tom Polen

CEO and President

Our Q3 financial results reflect the impact of COVID-19 during the quarter, with encouraging trends in June and July

Interventional	Medical	Life Sciences
Sequential	Impacted by lower	Strong demand for
improvement each	hospital utilization,	COVID-19 diagnostics,
month as elective and	with demand for	offset by lower capital
non-urgent procedures	medical consumables	investments and deferral
begin to resume	improving in June	of routine lab work

BD is well positioned to support customers through the pandemic

and to return to growth as healthcare continues to stabilize and recover.

BD is uniquely positioned to advance COVID-19 solutions across the continuum of care

CONTINUUM OF CARE

Discovery

Diagnosis

Delivery of care & treatment of disease

Life Sciences

Improving diagnosis & selection of optimal treatment

• Enabling	• Expanding rapid
research to	diagnostic &
understand	point-of-care
immune	testing &
response	surveillance

Medical	Interventional
Optimizing core healthcare	Advancing technologies to
delivery processes	treat high-burden diseases &
• Enabling medication	conditions

management and	• Ensuring critical
delivery	care & treatment
• Anticipating & preparing	for high-burden
conditions
for a worldwide
vaccination campaign

Informatics: integrated workflow management and data analytics

Advancing innovation and launching new diagnostic

solutions to help the world's response to COVID-19

Point-of-care antigen

Rapid and reliable testing at the point of care:

Confirms active COVID-19 infection in
15 minutes
Installed base of >25,000 across U.S.
Expect to deliver 10 million tests by September
Ramping production to 12 million tests per month at end of February 2021

BD Veritor™

Plus System

BD Synapsys™

Patient

Management

Molecular PCR

Easy-to-use,real-time PCR tests on

BD MAX™

EUA & CE-markedCOVID-19assays
Confirms active COVID-19 infection in
2-3 hours
Currently produce 1 million tests/month
Ramping production to 1.9 million tests/month by end of calendar year 2020

BD MAX™

Molecular System

Leveraging our manufacturing capabilities and scale to help the world prepare to deliver a COVID-19 vaccine

Global orders for 470 million injection devices to date:

				Other

190 million	75 million	65 million	140 million

Investing to expand injection device manufacturing capacity in the U.S.
- Through a public-private partnership, BARDA will invest an estimated $42 million into the $70 million capital project.
Expect majority of orders to be delivered in FY21

We are continuing to actively discuss injection device needs with

governments around the world.

FY 2020 Planned Product Launches:

Robust pipeline drives growth with innovative solutions

Medical

BD Provena™	BD Provena™	BD PowerMidline™	BD InSyte™	BD Intraosseous	BD Pyxis™	BD Intevia™	BD HealthSight™:	BD Ultrasafe	BD Hylok™
Solo	Midline Catheter	Catheter with	Autoguard™	Vascular Access	Logistics 1.2	1ml	MedSafety, Clinical	Plus™ 2.25	for IV
	with Max Barrier+	Max Barrier+	BC Pro	Device			Advisor & Infusion
	Kits	Kits					Diversion

Life Sciences

BD Synapsys™	BD COR™	BD Kiestra™	BD Kiestra™	BD MAX™	BD	BD OptiBuild™	BD Veritor™	BD	BD FACSDuet™	BD Eclipse™
3.1	GX/PX with	IdentifA	ReadA	COVID-19	FACSymphony™	Reagents	COVID-19 POC	FACSMelody™	Enhancements	Ultrafill Blood
	Onclarity™		Compact	Assays	S6 Sorter		Antigen Test	4-way Sorting		Collection
										Safety Needle

Interventional

SureStep™

Ultraverse™

Lutonix® AV

Caterpillar™

WavelinQ™

Dry-Doc™

Elevation™

3D Max™

Layered

Arctic Sun® Stat

Bone Biopsy

Vacutainer®

014 and 018

Low Profile

Embolization

4F+

Vacuum

Breast Biopsy

PurPrep™

MID

Non-woven

Temperature

Device

Station

Device

Hemostat

Management

System

Previously launched

New launch since last quarter

Advancing our long-term strategy to emerge strong and better positioned for value creation

Strong focus on cash and expense management
Project Recode remains on track
Operating with discipline to maximize impact

INNOVATIONEFFICIENCY

ACCESSEMPOWERMENT

Access the report at

http://bd.com/sustainabilty

Q3 results and COVID-19 impact

Chris Reidy

Executive Vice President, CFO and Chief Administrative Officer

Continuing to create and deliver value to all stakeholders

Continue to prioritize and adapt to the needs of our associates and customers around the world

Rapidly expanding our portfolio of solutions to address the COVID-19 pandemic

Focused on execution as our long-term strategy remains intact

Financial results: Q3 FY 2020

Revenue

Growth

Margin Expansion

Capital Deployment

Q3 revenue growth impacted by (~$600M) related to COVID-19

Q3 operating margins impacted by rich decremental margins of lost COVID revenues as expected

Retired $1.9B term-loan and $695M outstanding balance on revolver

	Q3	YTD
Revenues	$3,855	$12,333
FXN % growth	(9.4%)	(1.6%)
COVID impact	~(1,400 bps)

% growth	(11.4%)	(2.9%)
Adjusted OIBT (1)	$773	$2,837
% of revenues	+20.1%	+23.0%

Margin expansion (FXN)	(480 bps)	(150 bps)
Adjusted EPS (1)	$2.20	$7.41
FXN % growth	(25.0%)	(9.7%)

% growth	(28.6%)	(11.5%)

Net COVID impact of (~$600M) in Q3 FY 2020

Q3 COVID

headwinds of

(~$800M) driven by:

Q3 COVID

tailwinds of

~$200M

driven by:

Reduced elective procedure impacting Surgery & PI
Reduced hospital admissions resulting in lower procedure volumes, impacting medical device consumables in MDS and MMS
- Consequently, saw distributor inventory levels re-balance down after surge increases in March/April
Lower non-COVID diagnostic testing impacting DS and PAS and lower research activity impacting BIO
Some delays in capital instrument installations across the businesses (e.g. MMS, DS, BIO)
Pleased to see sequential monthly improvement from May to June in the COVID impact related to acute care admissions / procedures (MDS) and Non-COVIDtesting (IDS), and sequentially throughout the quarter in elective procedures (Surgery and PI)
COVID-19testing on BD MAX and global infusion pump demand
- ~$100M from BD MAXTM in Q3
- Majority of Alaris medical necessity demand occurred in April as expected

Medical segment revenue

Medication Delivery Solutions: $781

Q3	(17.8%)	YTD	(6.4% )
	(20.3%)		(8.1%)

Reduced hospital admissions due to COVID-19 leading to lower demand across the portfolio. Additionally, lower volumes in China due to the tendering process

Q3 COVID impact: ~(2,000 bps)

Medication Management Solutions: $677

Q3	+3.9%	YTD	(3.6%)
+2.5%	(4.4%)

Strong demand for infusion pumps in the U.S. under 'medical

necessity' in April, as well as strong International growth of pumps. Partial offsets include delayed capital installations of Dispensing systems and lower demand of infusion sets

Q3 COVID impact: ~1,000 bps

$2,122

(6.0%) FXN

COVID impact:~(600 bps)

(8.2%) Growth

YTD

$6,362

Pharmaceutical Systems: $403

Q3	+4.4%	YTD	+8.1%	Growth driven by pre-fillable syringes and also reflects timing

+2.3%	+6.0%	of customer orders that occurred in the first half of the year

(2.5%) FXN

(4.0%) Growth

Diabetes Care: $260

Q3	(2.9%)	YTD	+0.1%
(5.5%)	(1.5%)

Distributors and retailers reduced inventory, as expected, after increasing inventory in March due to COVID-19

Q3 COVID impact: ~(400 bps)

FXN % growth % growth

Life sciences segment revenue

Diagnostic Systems: $402

$951

(7.8%) FXN

Q3	+12.1%	YTD	+10.4%
	+9.3%		+8.7%

Performance driven by increased demand for COVID-19 related testing on BD MAXTM partially offset by a significant decline in non-COVID-19 diagnostic testing

Q3 COVID impact: ~(100 bps)

COVID impact:~(1,700 bps)

(10.1%) Growth

YTD

$3,187

+2.2% FXN

+0.7% Growth

Preanalytical Systems: $312

	(21.0%)		(3.1%)	Significant decline in routine specimen collections due
Q3	YTD	to COVID-19
(23.3%)	(4.8%)
		Q3 COVID impact: ~(2,500 bps)

Biosciences: $237

	(14.7%)		(1.4%)	Reduced demand for instruments and reagents as research
Q3	YTD	and clinical lab activity slowed due to COVID-19
(16.4%)	(2.6%)
		Q3 COVID impact: ~(2,500 bps)

FXN % growth	% growth	Note: COVID impact represents BD's estimate of the net financial impact of the global COVID-19 pandemic on the Company's
results. Revenue growth rates are not adjusted to reflect the impact of COVID-19.

Interventional segment revenue

Peripheral Intervention: $318

$782

(19.2%) FXN

Q3	(18.2%)		YTD	(3.4%)
(19.8%)		(4.6%)

COVID-19 negatively impacted demand for elective procedures in Oncology within the U.S., Europe and China and ESKD and PAD in the U.S. and Europe. Sequential improvement seen across all platforms during the quarter.

Q3 COVID-19 impact: ~(2,800 bps)

COVID Impact:~(3,000 bps)

(20.3%) Growth

YTD

Surgery: $197

Q3	(35.8%)		YTD	(9.5%)
(36.5%)		(10.0%)

COVID-19 negatively impacted demand for hernia repair and infection prevention in the U.S. and Europe as well as biosurgery in the U.S.

Q3 COVID-19 impact: ~(4,200 bps)

$2,784

Urology & Critical Care: $268

(3.7%) FXN

(4.4%) Growth

Q3	(2.0%)		YTD	+2.4%
(3.0%)		+2.0%

Impact of COVID-19 seen in acute urology due to lower hospital utilization partially offset by solid performance in TTM and Home Care

Q3 COVID-19 impact: ~(1,800 bps)

FXN % growth % growth

Adjusted gross and operating margins: Q3 FY 2020

Adjusted

Gross

margin

Adjusted

Operating

margin

55.6%
									0.5%	51.7%

				(3.9%)					(0.5%)

					~80% decremental margin
					from the mix of impacted
					revenues, high fixed costs
					and investments

		Q3 2019	COVID Impact	Leverage	Currency	Q3 2020


25.4%
						0.7%		20.1%
				(4.9%)				(0.6%)	(0.5%)



			Gross Profit COVID impact	(3.9%)
			Increased shipping costs	(0.5%)
			Additional investments	(0.5%)

	Q3 2019	COVID Impact	Leverage	Deferred Comp	Currency		Q3 2020

Adjusted income statement: Q3 FY 2020

As Adjusted (1)	Q3 FY 2020	% Growth	% FXN Growth
Revenues	$3,855	(11.4%)	(9.4%)

Gross Profit	1,993	(17.6%)	(15.1%)
% of revenues	51.7%
SSG&A	979	8.8%	6.7%
% of revenues	25.4%
R&D	241	0.3%	(0.2%)
% of revenues	6.3%
Operating Income	773	(30.0%)	(26.6%)
% of revenues	20.1%
Interest/Other, Net	97

Tax Rate	5.0%
Net Income	642	(27.4%)	(23.6%)
Preferred Dividend	9
Share Count	291.5
Adjusted EPS	$2.20	(28.6%)	(25.0%)
Gore royalty impact		(580 bps)

Note: Above figures reflects favorable / (unfavorable) performance versus last year.

Macro view of COVID-19 impact as of August 6th and key considerations looking forward

Macro

view of

COVID-19

impact

Varying degrees of the COVID-19 pandemic around the world, including infection levels, recovery and resurgence, and the ongoing uncertainty in general healthcare utilization levels
Expect a weaker global macroeconomic environment will pressure healthcare systems
Pace of elective procedure return will depend on several factors including disease condition and acuity, COVID-19 testing availability, varying status of "reopening" of countries around the world and patient willingness to seek care
Timing, effectiveness and rollout of a potential COVID-19 vaccine around the world and the resulting impact on surveillance testing

Elective Procedures	Acute Care / Non-Acute	Diagnostic Testing	Research & Clinical Labs

SURG, PI	MDS, MMS, UCC	IDS (DS & PAS)	BIO

Looking forward

Variability to timing of return to pre-COVID procedure levels
Closely watching the ongoing COVID resurgence in the U.S.

Monitoring hospital admission and utilization levels, for both COVID and non-COVID patient care
Watching for shift of care to non-acute settings
Demand for Alaris infusion pumps in the U.S. under medical necessity not expected to continue at the same level

Monitoring COVID and non- COVID testing volumes globally
Impact on capital equipment purchases
Demand for our COVID-19 testing on BD VeritorTM and
BD MAXTM

Levels of research activity and clinical testing, including timing of when research institutions will resume and scale up to normal operations, along with capital spending

COVID-19 impact on Q3 revenues and key observations

Note: Dollar and growth percentages reflect estimated COVID-19 revenue impact vs. pre-COVID expectations (Does not reflect year-over-year growth.)

Elective Procedures	Acute / Non-Acute Care	Diagnostic Testing	Research & Clinical Labs

SURG (~$130M)	MMS +~$65M	IDS (DS & PAS)	BIO (~$70M)
PI (~$110M)	MDS (~$200M); UCC (~$50M)	(~$105M)

● Procedure declines due to

deferrals with sequential

improvement during Q3;

Overall procedure decline

better than expected

● Varies by category: Impact

across PI and Surgery

platforms ranged from

(i~25%) to (i~40%)

● Around the world:

Surgery/PI procedures

impacting US/Europe revenues

(i~35%); China Surgery/PI

● Procedure declines and lower

volumes impacting WW MDS

revenues across the world,

primarily U.S. and China (US

i25%, China i30%, and Europe

i5%; all with volumes improving

sequentially in June)

● Demand for infusion pumps

• In U.S. under 'medical

necessity', which slowed in

May/June after initial April

surge demand, as expected

High demand for BD COVID tests (BD MAXTM testing plus transport media and lancets)
Decreased non-COVID 19 BD diagnostic testing and specimen collection revenues (i~30%), driven by U.S., Europe and Asia
Q3 delays in large capital installations (Kiestra)

Decrease in research activity due to lab closures and reduced clinical testing revenues (i~25%)
Q3 delays in instrument installations

revenues (i~15%)

• Strong demand surge of

pumps outside U.S.

● Q3 delays in instrument

installations (Pyxis, ROWA)

Estimate (~$600M) COVID-19 impact to Q3 BDX revenues

Preliminary July observations

Saw sequential improvement in recovery to pre- COVID levels

COVID-19 testing

demand

Other observations

Elective procedure volumes improved from ~80% in June to ~85% in July
TheU.S.impacthospitalfromadmissionslower U.S. improvedhospital admissionsnd continue improvedto be ~80%fromto ~805% inof Junepre-COVIDto~85%levelsin July
NContinued-COVIDrecovery-19 diagnosticin Non-COVIDtesting-19anddiagnosticspecimentestingcollectionandimprovedspecimenfromcollection~75% indemandJune tofrom~80%~75%in Julyin June to ~80% in July
Continued demand for COVID-19 tests on BD MAXTM and transport media
Early strong demand of Veritor antigen test for rapid detection of COVID-19
Small amount of Alaris medical necessity demand as expected
Continued delays in large capital installations as expected

Q4 and FY 2020 guidance

	Revenue
	FXN and reported revenue
Q4	expected to be down low-
	single digits
	FXN %: (2.0%) to (1.5%)
Full-	FX Impact: (~1%)
year
Reported %: (3.0%) to (2.5%)

Adjusted EPS (1)

Adjusted EPS expected to be

$2.40 to $2.60

Adjusted EPS: $9.80 to $10.00

Adjusted FXN %: (~14.5%) to (~12.5%)

Adjusted EPS %: (~16.0%) to (~14.0%)

Key takeaways

Continue to be uniquely positioned to respond to COVID-19by leveraging

our core capabilities across research, diagnosis and patient care

Third quarter results reflect encouraging trends in June

Establishing guidance for fiscal fourth quarter and full-year

as we have improved near-term visibility

Remain focused on executing our long-term strategy and delivering value

for customers, patients and shareholders

Advancing our long-term strategy to emerge strong and better positioned for value creation

Geographic revenue highlights

Q3 revenue $ and FXN growth

Q3 COVID Impact

$2,119

United States

~(15%) / ~($370M)

(13.1%)

		$1,735		International
		(4.7%)

	$3,283			Developed Markets

	(8.8%)

$572				Emerging

(12.9%)
			Markets

$250

China

(17.0%)

~(12%) / ~($230M)

~(12%) / ~($450M)

~(21%) / ~($150M)

~(22%) / ~($70M)

*See appendix.

Impact: Delivering long-term value for all stakeholders

Management Approach	Q3 Update

Grow

Empower Simplify

INNOVATION

ACCESS

EFFICIENCY

EMPOWERMENT

Develop and maintain a strong portfolio of leading products and solutions that address significant unmet clinical needs, improve outcomes, and reduce costs

Leverage our global scale to expand our reach in providing access to affordable medical technologies around the world

Work across our supply chain to

minimize environmental impacts and create more resilient operations, including an enterprise-wide renewable energy strategy

Foster a purpose-driven culture

with a focus on positive impact to all stakeholders - customers, patients, employees and communities

BD introduced the Halo One™ Thin-Walled Guiding Sheath which reduces the size of the arteriotomy compared to standard sheaths of equivalent French size, which is designed to help minimize access site complications.
BD deployed the BD Bactec FX ™ and other IDAST platforms across
25 labs in Sub-Saharan Africa and Asia as part of the Fleming Fund and UK Aid Award to address the global AMR challenge
BD reported* progress against our 2020 Sustainability goals in July, achieving our targets to reduce Scope 1 & 2 GHG emissions and water consumption ahead of schedule. In support of the recommendations of the Task Force on Climate-related Financial Disclosures, our Climate

Management report will be available late summer.

BDs partnership with Planet Water continued, funding the installation of water towers in Mexico. These towers will provide clean and safe water for students in two communities.

Looking forward to sharing our 2030+ impact goals later in 2020

FY 2019 Sustainability Report

BD launched its FY 2019 Sustainability Report in July 2020.

Highlights from this year's report include:

Innovation: In FY 2019 BD launched 25 major products across the company, each of which moved our innovation goals forward. The report highlights a number of these products.

Access: BD was recognized by Forbes Magazine, naming us to its "Change the World List" for the company's extensive efforts in helping combat the threat of antimicrobial resistance (AMR).

Efficiency: BD has continued to reducing its impact on the environment through reduced greenhouse gas emissions and water consumption and remains committed to waste reduction and increasing use of renewable energy.

Empowerment: BD received recognition from a number of organizations for its work towards fostering an environment that welcomes and empowers an inclusive and diverse workforce.

Access the report at www.bd.com/sustainabilty

Estimated COVID-19 impact on preliminary April revenue results and key observations

Elective Procedures	Acute / Non-Acute Care	Diagnostic Testing	Research & Clinical Labs

SURG (~$60M)	MMS +~$70M	IDS (DS & PAS)	BIO (~$20M)
PI (~$50M)	MDS (~$50M); UCC (~$20M)	(~$40M)

Significant procedure declines due to mandates to defer elective procedures and 'stay at home' orders

Varies by category: Decrease in hernia and other elective procedures impacting Surgery revenue (i50-70%),and slowdown in Oncology, ESKD & PAD procedures impacting PI revenue (i30- 40%)

Demand for infusion pumps under 'medical necessity'; not expected to continue at same pace

Delays of instrument installations (Pyxis, ROWA)

Significant procedure declines impacting US MDS revenue (i15-20%vs. pre-COVIDexpectations)

China utilization: hospital

Decreased non-COVID 19 BD diagnostic testing and specimen collection revenue (i20-30%),largest impact in the U.S.

High demand for BD COVID tests (Molecular and Serology, transport media and lancets)

Expect delays in large capital installations (Kiestra)

Decrease in research activity due to lab closures and reduced clinical testing revenue (i20-30%);expect slightly larger impact in coming months

Expect impact on capital spending

Around the world: China Surgery revenues tracking to ~50% of pre-COVIDexpectations; and Surgery and PI procedures impacting revenue (i60 to 90%) in US/Europe

volumes broadly returning, but still ~30% to 40% below pre- COVID expectations

Europe: some COVID surge demand continued; revenue ~h5% above pre-COVID expectations

Estimate (~$240M) COVID-19 impact to our preliminary April BDX revenues, partially offset by ~$70M positive impact in MMS

Note: April revenue results are preliminary and unaudited, and are uncertain and subject to change when we prepare our consolidated financial statements for the three and nine months ended June 30, 2020. Actual results may differ materially from the revenue results discussed herein. Revenue dollar and growth percentages reflect estimated performance vs. pre-COVID expectations.

Q3 FY 2020 & Q3 FY 2019 Adjustment Reconciliations

YTD Q3 FY 2020 & YTD Q3 FY 2019 Adjustment Reconciliations

Q3 FY 2020 Reconciliation of Reported Diluted EPS to Adjusted Diluted EPS

YTD Q3 FY 2020 Reconciliation of Reported Diluted EPS to Adjusted Diluted EPS

Q3 and YTD FY 2020 Reconciliation - FX Impact Emerging, Developed Markets & China

FY 2020 Revenue & EPS Outlook Reconciliation

YTD Q3 FY 2020 Operating Cash Flow Reconciliation

(Unaudited, Amounts in billions)
Reported Operating Cash Flow	$	2.1
Adjustments (excludes non-cash items)
Restructuring costs		0.0
Integration costs		0.2
Transaction gain/loss and product-related matters		0.2
Other		0.4
Tax impact related to items above		(0.1)
Adjusted Operating Cash Flow	$	2.8

Attachments

Original document
Permalink

Disclaimer

BD - Becton, Dickinson and Company published this content on 06 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 August 2020 10:08:21 UTC

Latest news about Becton, Dickinson and Company

Becton Dickinson Releases New Image-Enabled Cell Sorters	Apr. 05	MT
Becton, Dickinson and Company Increases Access to Cutting-Edge Image-Enabled, Spectral Cell Sorters	Apr. 05	CI
AngioDynamics Settles Patent Dispute with Becton, Dickinson Affiliate	Apr. 01	MT
AngioDynamics Settles Multi-Year Patent Dispute with Becton Dickinson & Co	Apr. 01	DJ
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	Mar. 21	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	Mar. 21	MT
Sector Update: Health Care	Mar. 21	MT
Becton, Dickinson Raising Domestic Production of Syringes	Mar. 21	MT
Transcript : Becton, Dickinson and Company Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:30 AM	Mar. 13
Becton, Dickinson and Co. Enrolls First Person in Trial of Stent to Treat Peripheral Arterial Disease	Mar. 04	MT
Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease	Mar. 04	CI
Transcript : Becton, Dickinson and Company Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 08:00 AM	Feb. 29
Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024	Feb. 27	CI
Becton, Dickinson Seeks M&A	Feb. 26	CI
Transcript : Becton, Dickinson and Company - Special Call	Feb. 26
Becton, Dickinson Collaborating With Camtech Health for at-Home Cervical Cancer Screening in Singapore	Feb. 21	MT
Barclays Adjusts Price Target on Becton Dickinson and Co. to $305 From $301, Maintains Overweight Rating	Feb. 05	MT
Tranche Update on Becton, Dickinson and Company's Equity Buyback Plan announced on November 4, 2021.	Feb. 01	CI
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	Feb. 01	MT
Transcript : Becton, Dickinson and Company, Q1 2024 Earnings Call, Feb 01, 2024	Feb. 01
Becton, Dickinson's Fiscal Q1 Adjusted Earnings Down, Revenue Up; 2024 Guidance Revised	Feb. 01	MT
Becton Dickinson Lifts 2024 Outlook After Sales Rise in 1Q	Feb. 01	DJ
(BDX) BD (BECTON DICKINSON AND COMPANY) Sees Fiscal Year 2024 EPS Range $12.82 - $13.06	Feb. 01	MT
Earnings Flash (BDX) BD (BECTON DICKINSON AND COMPANY) Posts Q1 Revenue $4.71B, vs. Street Est of $4.73B	Feb. 01	MT
Earnings Flash (BDX) BD (BECTON DICKINSON AND COMPANY) Posts Q1 EPS $2.68, vs. Street Est of $2.40	Feb. 01	MT

Chart Becton, Dickinson and Company

Duration

Period

More charts

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-02 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Becton, Dickinson and Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

230.5 USD

Average target price

281.2 USD

Spread / Average Target

+22.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BECTON, DICKINSON AND COMPANY	-5.48%	66.59B
ABBOTT LABORATORIES	-2.92%	185B
MEDTRONIC PLC	-3.80%	105B
DEXCOM, INC.	+11.22%	54.66B
CENCORA, INC.	+16.74%	47.78B
HOYA CORPORATION	+3.89%	41.26B
WEST PHARMACEUTICAL SERVICES, INC.	+4.56%	26.95B
METTLER-TOLEDO INTERNATIONAL, INC.	+1.64%	26.37B
TERUMO CORPORATION	+13.20%	24.8B
ZIMMER BIOMET HOLDINGS, INC.	-1.60%	24.6B

Other Medical Equipment, Supplies & Distribution